Equities research analysts expect AC Immune SA (NASDAQ:ACIU) to announce sales of $900,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AC Immune’s earnings. The lowest sales estimate is $600,000.00 and the highest is $1.20 million. AC Immune posted sales of $33.90 million in the same quarter last year, which suggests a negative year-over-year growth rate of 97.3%. The company is expected to issue its next earnings report on Wednesday, November 11th.
On average, analysts expect that AC Immune will report full-year sales of $15.74 million for the current fiscal year, with estimates ranging from $14.24 million to $17.77 million. For the next year, analysts anticipate that the firm will report sales of $71.07 million, with estimates ranging from $61.80 million to $80.33 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for AC Immune.
A number of research firms recently issued reports on ACIU. BidaskClub cut shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Friday, July 24th. Zacks Investment Research cut shares of AC Immune from a “buy” rating to a “sell” rating in a research report on Tuesday, August 11th. Finally, TheStreet cut shares of AC Immune from a “c” rating to a “d+” rating in a research report on Tuesday, May 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.25.
A number of hedge funds and other institutional investors have recently made changes to their positions in ACIU. Acadian Asset Management LLC increased its position in AC Immune by 132.8% in the 1st quarter. Acadian Asset Management LLC now owns 747,781 shares of the company’s stock valued at $5,164,000 after acquiring an additional 426,542 shares during the period. Prosight Management LP increased its position in AC Immune by 11.2% in the 2nd quarter. Prosight Management LP now owns 1,176,801 shares of the company’s stock valued at $7,920,000 after acquiring an additional 118,104 shares during the period. Verition Fund Management LLC increased its position in AC Immune by 303.6% in the 2nd quarter. Verition Fund Management LLC now owns 138,991 shares of the company’s stock valued at $935,000 after acquiring an additional 104,557 shares during the period. Private Advisors LLC acquired a new position in AC Immune in the 1st quarter valued at approximately $507,000. Finally, AJO LP acquired a new position in AC Immune in the 1st quarter valued at approximately $370,000. Hedge funds and other institutional investors own 30.16% of the company’s stock.
NASDAQ:ACIU traded down $0.42 during trading hours on Thursday, hitting $7.29. 219,100 shares of the stock traded hands, compared to its average volume of 285,943. The firm has a 50 day moving average price of $7.17 and a 200 day moving average price of $7.07. The firm has a market cap of $492.53 million, a price-to-earnings ratio of -19.70 and a beta of 0.59. AC Immune has a fifty-two week low of $4.07 and a fifty-two week high of $13.00. The company has a current ratio of 20.63, a quick ratio of 20.63 and a debt-to-equity ratio of 0.01.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Story: Elliott Wave Theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.